Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Prognostic factors associated with overall survival in patients with Merkel cell carcinoma: A retrospective analysis in a Mexican cohort at a tertiary referral center in Latin America.

Javier Antonio Méndez López, Elí Emmanuel Santana Aguilar, Cristian Ramon Vargas Arevalo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21571

e21571 Background: Merkel cell carcinoma is a rare but highly aggressive neuroendocrine neoplasm of the skin. It predomina...

The impact of COVID-19 mRNA vaccination on bispecific antibody outcomes in hematologic malignancies: A retrospective multicenter cohort study.

Mostafa Eysha, Ekrem Turk, Mohanad Elchouemi et al. Jun 01, 2026 pp. 7040-7040 10.1200/jco.2026.44.16_suppl.7040

7040 Background: Bispecific antibody (BsAb) therapies are universally available, off-the-shelf therapies and are increasin...

Bispecific antibodies in breast cancer: A systematic landscape analysis of clinical trials.

Trie Arni Djunadi, Falak Naz, Sai Sushrutha Mudupula Vemula et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14503

e14503 Background: Bispecific antibodies (BsAbs) engage two targets to enhance antitumor activity and potentially overcome...

Pharmacogenetic (PGx) markers of cardiovascular side effects (CVSEs) in allogeneic hematopoietic cell transplant (HCT) patients receiving post-transplant cyclophosphamide (PTCy).

Neha Deshpande, Wei Sha, Simeon Owuor et al. Jun 01, 2026 pp. 6559-6559 10.1200/jco.2026.44.16_suppl.6559

6559 Background: PTCy is used to prevent graft versus host disease (GVHD) post-HCT. CVSEs can be observed with Cy. We prev...

Time to response with HMA/venetoclax as a predictor of survival in acute myeloid leukemia: Analysis of 1- vs 2-cycle responders.

Rafeh Safdar, Chandra Kakarala, Reema Anjum et al. Jun 01, 2026 pp. 6548-6548 10.1200/jco.2026.44.16_suppl.6548

6548 Background: Hypomethylating agents (HMA) with venetoclax are the standard of care for patients with AML ineligible fo...

Targeting nitrogen metabolism in hepatocellular carcinoma.

Ameer L. Elaimy, Theodore Steven Lawrence Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15101

e15101 Background: Hepatocellular carcinoma (HCC) commonly develops in patients with cirrhosis, a condition associated wit...

In-person versus telehealth outpatient palliative care visits in oncology: A multicenter study.

Sarah Ananda Gomes, Flavia Santos Dumont Sorice, Cecilia Emerick Mendes Vaz et al. Jun 01, 2026 pp. 12056-12056 10.1200/jco.2026.44.16_suppl.12056

12056 Background: As telehealth becomes integral to outpatient palliative care delivery in oncology, evidence comparing co...

Burden of bladder cancer across Asia: Insights from the Global Burden of Disease (1999–2023).

Areesha Mansoor, Sarim Hassan Shahab, Sanhia Maheshwari et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16617

e16617 Background: Bladder cancer is a malignant neoplasm arising from uncontrolled growth of the urothelial lining and re...

Melanoma stage as influenced by 31-GEP risk prediction.

J. Michael Guenther, Chase Guenther Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21604

e21604 Background: 31-gene expression profiling (31-GEP) has demonstrated the ability to predict the risk of recurrence (R...

Role of ATM as a prognostic biomarker in breast cancer: A systematic review and meta-analysis.

Muhammad Abdul Moiz, Amina Hassan, Muhammad Junaid Iqbal et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12705

e12705 Background: Breast cancer is the most common malignancy among women worldwide and remains a leading cause of cancer...

Real-world safety of elranatamab in low-weight patients: Findings from the SUMMIT study.

Satoshi Yoshihara, Aster Meche, Arianne Faucher et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23364

e23364 Background: Elranatamab is the first BCMA bispecific antibody approved in Japan for treatment of patients with heav...

Prognostic significance of STK11, KEAP1, and NFE2L2- mutations in lung squamous cell carcinoma treated with immunotherapy with or without chemotherapy.

Sheng Liew, Mark Yungjie Jeng, Lingzhi Hong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20635

e20635 Background: Mutations in STK11 and KEAP1 are consistently associated with poor prognosis in NSCLC. In the lung squa...

A study on the application of metaproteomic and serum metabolomic integration analysis in TACE combined with targeted immunotherapy for unresectable hepatocellular carcinoma.

Yingming Gao, Xiaolong Ge, Zhengguang Guo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16207

e16207 Background: TACE combined with targeted therapy and immunotherapy represents a potentially effective therapy for uH...

External validation of a MMAI model for prognosis and chemotherapy benefit prediction in postmenopausal, node-positive, hormone receptor–positive breast cancer patients: Analysis of SWOG S8814.

Corey Wayne Speers, Alexander Piehler, Allison Meisner et al. Jun 01, 2026 pp. 107-107 10.1200/jco.2026.44.16_suppl.107

107 Background: Despite effective endocrine therapy, the absolute benefit of adjuvant chemotherapy varies widely in node-p...

Association of high baseline thymidine kinase 1 activity with poor prognosis in breast cancer patients across different molecular subtypes and treatments.

Amirta Devi, Tornike Zabakhidze, Ghulam Shah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13093

e13093 Background: Despite advances in diagnostics, there is an unmet need of biomarkers able to foresee breast cancer pro...

Temporal changes in mortality among adults with breast cancer and diabetes mellitus in the United States.

Sufia Ahmed Jun 01, 2026 pp. 1116-1116 10.1200/jco.2026.44.16_suppl.1116

1116 Background: Breast cancer and diabetes mellitus represent major and intersecting public health challenges in the Unit...

Cumulative barriers to access: An AI-driven analysis of eligibility restrictions, clinical setting, and molecular gatekeeping in 509 interventional glioblastoma trials (2016-2025).

Andrew Ng, Sudeep Kumar Siddappa Malleshappa, Wilson C. Mertens Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14065

e14065 Background: The 2021 WHO Classification redefined glioblastoma (GBM) via strict molecular parameters. It is unclear...

Negative effect of malignant pleural effusion on the efficacy of immunotherapy via IL-6–mediated abscopal immunosuppression in advanced non-small cell lung cancer.

Yaping Guan, Yuekai Zhang, Yue Dong et al. Jun 01, 2026 pp. 12059-12059 10.1200/jco.2026.44.16_suppl.12059

12059 Background: The present study is designed to determine the effect and mechanism of malignant pleural effusion (MPE)...

Beyond KIT and PDGFRA: Molecular landscape and outcomes of wild-type GIST.

Maximilian Brockwell, Romil Patel, Mary Wandel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23518

e23518 Background: Gastrointestinal Stromal Tumors (GIST) are rare mesenchymal neoplasms of the gastrointestinal tract. Mo...

Survival with Bria-IMT + CPI in advanced metastatic breast cancer at 12 and 24 months.

Chaitali Nangia, Saranya Chumsri, Kendrith M. Rowland et al. Jun 01, 2026 pp. 1108-1108 10.1200/jco.2026.44.16_suppl.1108

1108 Background: Metastatic breast cancer (MBC) remains limited by resistance and cumulative toxicity in heavily pretreate...

Denosumab versus zoledronic acid in patients with breast cancer: A propensity-matched real-world time-to-event analysis.

Mohammad Salameh, Jamil Nazzal, Bugra Zengin et al. Jun 01, 2026 pp. 12079-12079 10.1200/jco.2026.44.16_suppl.12079

12079 Background: Bone-modifying agents are routinely used in patients with breast cancer to reduce skeletal-related compl...

Standardizing patient-initiated electronic messaging in a high-volume breast center.

Stav Dor Cullum, Sharon Kuruvilla, Dharusal Patel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13557

e13557 Background: Patient-initiated electronic messaging volume has risen nationally, with a 30% annual increase in medic...

RISE trial: A novel virtually delivered supervised exercise intervention targeting cognitive impairment and gut microbiome in adolescent and young adult (AYA) brain tumor survivors.

Elizabeth Pan, Maria Chang Swartz, Keri L. Schadler et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps12167

TPS12167 Background: Up to 45% of AYA brain tumor survivors experience cancer-related cognitive impairment (CRCI) affectin...

Adjuvant pembrolizumab in clear cell renal cell carcinoma with high recurrence risk: A multicenter real-world study.

Liangyou Gu, Yicong Du, Shimiao Zhu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16538

e16538 Background: Pembrolizumab has demonstrated efficacy in improving disease-free survival (DFS) and overall survival (...

Outcomes of a feasibility and safety trial of tile-based radiation therapy with cesium-131 followed by external beam radiation therapy with concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma (NCT05342883).

Clark C. Chen, Kris Smith, Lindsey Sloan et al. Jun 01, 2026 pp. 2011-2011 10.1200/jco.2026.44.16_suppl.2011

2011 Background: Standard of care (SOC) of Glioblastoma (GBM) includes maximal safe resection followed by external beam ra...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page